Genomic testing helps inform treatment intensity decisions in intermediate-risk prostate cancer

Data from a large real-world analysis presented at the American Society for Radiation Oncology 67^th Annual Meeting¹ suggests that treatment can be de-intensified for many patients with intermediate-risk prostate cancer. Drawing on genomic…